Abstract
The clinical efficacy, the bronchodilating effect and the side effects of two oral forms of terbutaline were compared in a double-blind, cross-over study involving ten patients with chronic reversible airways obstruction. The administration of plain-tablets, containing 2.5 mg terbutaline sulphate, three times daily at 6 h intervals was compared to the administration of slow-release (SR) tablets, containing 5 mg terbutaline sulphate, every 12 h. Each course of treatment lasted for 7 days. Treatment with SR-tablets resulted in significantly higher lung function values in the morning (PEFR at home and FEV1 at the lung function laboratory on day 7). There were no significant differences between the two forms with regard to symptom score, extra use of rimiterol aerosol, heart rate or blood pressure. The plasma terbutaline concentration in the morning of the seventh treatment day was significantly higher during SR-tablet treatment. The plasma terbutaline concentration curve showed a smaller peak/trough ratio for the SR-tablets.
Full text
PDF
Selected References
These references are in PubMed. This may not be the complete list of references from this article.
- Eriksson N. E., Haglind K., Ljungholm K. A comparison of sustained-release terbutaline and ordinary terbutaline in bronchial asthma. Br J Dis Chest. 1982 Apr;76(2):202–204. [PubMed] [Google Scholar]
- Jacobsson S. E., Jönsson S., Lindberg C., Svensson L. A. Determination of terbutaline in plasma by gas chromatography chemical ionization mass spectrometry. Biomed Mass Spectrom. 1980 Jun;7(6):265–268. doi: 10.1002/bms.1200070608. [DOI] [PubMed] [Google Scholar]
- Leferink J. G., van den Berg W., Wagemaker-Engels I., Kreukniet J., Maes R. A. Pharmacokinetics of terbutaline, a beta 2-sympathomimetic, in healthy volunteers and asthmatic patients. Arzneimittelforschung. 1982;32(2):159–164. [PubMed] [Google Scholar]
- Lönnerholm G., Foucard T., Lindström B. Oral terbutaline in chronic childhood asthma; effects related to plasma concentrations. Eur J Respir Dis Suppl. 1984;134:205–210. [PubMed] [Google Scholar]
- Nyberg L., Kennedy B. M. Pharmacokinetics of terbutaline given in slow-release tablets. Eur J Respir Dis Suppl. 1984;134:119–139. [PubMed] [Google Scholar]
- Nyberg L. Pharmacokinetic parameters of terbutaline in healthy man. An overview. Eur J Respir Dis Suppl. 1984;134:149–160. [PubMed] [Google Scholar]
- Taudorf E., Bundgaard A., Fagerström P. O., Weeke E., Weeke B. Terbutaline depot tablets in asthma. A clinical evaluation. Allergy. 1981 Oct;36(7):495–500. doi: 10.1111/j.1398-9995.1981.tb01861.x. [DOI] [PubMed] [Google Scholar]
- Van Den Berg W., Leferink J. G., Kreukniet J., Bruynzeel P. L. Correlation between terbutaline serum levels, c-AMP plasma levels and FEV1 in normals and asthmatics after subcutaneous administration. Ann Allergy. 1980 Apr;44(4):235–239. [PubMed] [Google Scholar]
- van den Berg W., Leferink J. G., Tabingh Suermondt W., Kreukniet J., Maes R. A., Serra R., Bruynzeel P. L. Terbutaline serum concentrations related to different lung function parameters and beta-receptor function. Int J Clin Pharmacol Ther Toxicol. 1983 Jan;21(1):24–30. [PubMed] [Google Scholar]